Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease

CNS Drugs

Volumn 15, Issue 5, 2001, Pages 375-390

  Imbimbo, Bruno Pietro ^a  

^a CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMINOACRIDINE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; NXX 066; PHYSOSTIGMINE; PLACEBO; QUILOSTIGMINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; VELNACRINE;

ALZHEIMER DISEASE; CHOLINERGIC STIMULATION; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MONITORING; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME INACTIVATION; HUMAN; META ANALYSIS; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STEADY STATE; TISSUE DISTRIBUTION; VOMITING;

EID: 0035012753     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115050-00004     Document Type: Review

References (88)

1. 1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34: 939-44
2. 2. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403
3. 3. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6
4. 4. Davies P. Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 1999: 281: 1433-4
5. 5. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-15
6. 6. Svensson AL, Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 227-35
7. 7. Thal LJ, Ferguson JM, Mintzer J, et al. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999; 52: 1146-52
8. 8. Eagger SA, Harvey RJ. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995:9 Suppl. 2: 37-42
9. 9. Kerkut GA. Acetylcholinesterase (AChE) (EC 3.1.1.7.). Gen Pharmacol 1984; 15: 375-8
10. 10. Appleyard ME. Non-cholinergic functions of acetylcholinesterase. Biochem Soc Trans 1994; 22: 749-55
11. 11. Massoulie J, Sussman J, Bon S, et al. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 1993: 98: 139-46
12. 12. Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989: 260: 625-34
13. 13. Mack A, Robitzki A. The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study. Prog Neurobiol 2000: 60: 607-28
14. 14. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-18
15. 15. Reiner E. Radic Z: Mechanism of action of cholinesterase inhibitors. In: Giacobini E. editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 103-19
16. 16. al-Jafari AA, Kamal MA, Alhomida AS. Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: kinetic characterization. J Biochem Mol Toxicol 1998; 12: 245-51
17. 17. Kryger G. Silman I, Sussman JL. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J Physiol Paris 1998; 92: 191-4
18. 18. Greenblatt HM, Kryger G, Lewis T, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 1999; 463: 321-6
19. 19. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487-92
20. 20. Yu QS, Atack JR, Rapoport SI, et al. Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl-and butyrylcholinesterase. FEBS Lett 1988; 234: 127-30
21. 21. Brossi A, Schonenberger B, Clark OE, et al. Inhibition of acetylcholinesterase from electric eel by (-)-and (+)-physostigmine and related compounds. FEBS Lett 1986 9; 201: 190-2
22. 22. Brufani M, Maria M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 1986; 157: 115-20
23. 23. Weinstock M, Razin M, Chorev M, et al. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994; 43: 219-25
24. 24. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996; 21: 331-7
25. 25. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 181-226
26. 26. Tago H, Maeda T, McGeer PL, et al. Butyrylcholinesterase-rich neurons in rat brain demonstrated by a sensitive histochemical method. J Comp Neurol 1992; 325: 301-12
27. 27. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993: 34: 373-84
28. 28. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998: 50: 136-45
29. 29. Imbimbo BP, Martelli P, Troetel WM, et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 1999; 52: 700-8
30. 30. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
31. 31. Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy 1998; 18 (2 Pt 2): 47-54
32. 32. Lotti M. Cholinesteras inhibition: complexities in interpretation. Clin Chem 1995: 41: 1814-8
33. 33. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74: 225-41
34. 34. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31
35. 35. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 1998; 50: 1214-21
36. 36. Imbimbo BP, Troetel WM, Martelli P, et al. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 17-23
37. 37. Wilcock G, Wilkinson D. Galantamine hydrobromide: interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Iqbal K, Winblad B, Nishimura T, et al, editors. Alzheimer's disease: biology, diagnosis and therapeutics. New York (NY): John Wiley & Sons Ltd, 1997: 661-4
38. 38. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-91
39. 39. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44
40. 40. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8
41. 41. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriat Psychopharmacol 1998: 1: 55-65
42. 42. Dubois B, McKeith I, Orgogozo JM, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973-82
43. 43. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
44. 44. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
45. 45. Wilcock GK, Lilienfled S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000: 321: 1445-9
46. 46. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-8
47. 47. Cultler NR, Sramek JJ. The role of bridging studies in the development of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 1998; 10: 355-64
48. 48. Nordberg A. Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety 1998; 19: 465-80
49. 49. Schneider LS. Metrifonate for Alzheimer's disease patients. J Clin Psychiatry 2000; 61: 218-9
50. 50. Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials. treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93-101
51. 51. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000; 356: 568
52. 52. Bourke D, Druckenbrod RW. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother 1998; 32: 610-1
53. 53. Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J Am Geriatr Soc 1998; 46: 119-20
54. 54. Bryant CA, Ouldred E, Jackson SHD, et al. Purpuric rash with donepezil treatment. BMJ 1998: 317: 787
55. 55. Lang IM. Noxious stimulation of emesis. Dig Dis Sci 1999; 44 (8 Suppl.): 58S-63S
56. 56. Stewart JJ, Burks TF, Weisbrodt NW. Intestinal myoelectric activity after activation of central emetic mechanism. Am J Physiol 1977; 233: E131-7
57. 57. Furman JM, Whitney SL. Central causes of dizziness. Phys Ther 2000; 80: 179-87
58. 58. Lazartigues E, Freslon JL, Tellioglu T, et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol 1998; 361: 61-71
59. 59. Karczmar AG. Synaptic, behavioral, and toxicological effects of cholinesterase inhibitors in animals and humans. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 157-80
60. 60. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98: 431-8
61. 61. Imbimbo BP. Lucca U, Lucchelli F, et al. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer's disease. Alzheimer Dis Assoc Disord 1998; 12: 313-22
62. 62. Knapp S, Wardlow L, Albert K, et al. Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos 1991: 19: 400-4
63. 63. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420-8
64. 64. Tiseo PJ, Rógers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 Suppl. 1: 13-8
65. 65. Imbimbo BP, Licini M, Schettino M. et al. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 1995; 35: 285-90
66. 66. Kennedy JS. Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999; 19: 513-21
67. 67. Ray DE. Chronic effects of low level exposure to anticholinesterases - a mechanistic review. Toxicol Lett 1998; 102-103: 527-33
68. 68. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449-57
69. 69. Johansson M, Hellstrom-Lindahl E, Nordberg A. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 1996; 7: 111-7
70. 70. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 7-12
71. 71. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetyicholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20: 634-47
72. 72. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38: 236-45
73. 73. Asthana S, Greig NH, Hegedus L, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995; 58: 299-309
74. 74. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 97: 244-50
75. 75. Unni L, Vicari S, Moriearty P, et al. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate. Methods Find Exp Clin Pharmacol 2000; 22: 57-61
76. 76. Schmidt BH, Heinig R. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9 Suppl. 2: 15-9
77. 77. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
78. 78. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S22-S32
79. 79. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52: 1324-33
80. 80. Flood JF, Landry DW, Jarvik ME. Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 1981; 215: 177-85
81. 81. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology 1985; 87: 266-71
82. 82. Nabeshima T, Yoshida S, Kameyama T. Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice. Eur J Pharmacol 1988; 154; 263-9
83. 83. Yamazaki N, Kato K, Kurihara E, et al. Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats. Psychopharmacology 1991; 103; 215-22
84. 84. Wanibuchi F, Nishida T, Yamashita H, et al. Characterization of novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 1994; 265: 151-8
85. 85. Braida D, Paladini E, Griffini P, et al. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 1996; 302: 13-20
86. 86. Marchi M, Paudice P, Raiteri M. Autoregulation of acetylcholine release in isolated hippocampal nerve endings. Eur J Pharmacol 1981; 73: 75-9
87. 87. Consolo S, Ladinsky H, Vinci R, et al. An in vivo pharmacological study on muscarinic receptor subtypes regulating cholinergic neurotransmission in rat striatum. Biochem Pharmacol 1987; 36: 3075-7
88. 88. Messamore E, Warpman U, Williams E, et al. Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition. Neurosci Lett 1993; 158: 205-8